Jiangsu Antae Biological Technology

Jiangsu Antae Biological Technology is a Chinese biotechnology company specializing in the development and industrialization of targeted immunotherapies and therapeutic vaccines for major viral diseases and cancers. Founded in 2007 by academician Xiaojun Yan, the company has established proprietary technology platforms including T-DC (Target-Dendritic Cell) cell therapy, SEA-MAP (Single Epitope Multimeric Antigen Peptide), and SMAP-AB (Single Epitope Specific Antibody Platform). Its pipeline features therapeutic vaccines targeting chronic hepatitis B, hepatocellular carcinoma (which received US FDA Orphan Drug Designation in 2018), cervical cancer (HPV), and nasopharyngeal carcinoma. Antae Biological operates a state-of-the-art cell therapy manufacturing facility that recently achieved GMP compliance certification, positioning it to advance its clinical-stage cell therapies toward commercialization.